Evidence map›Paper›PMID 38651550›Full record

SynthesisActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale2024

A systematic review of randomised controlled trials on topical nasal steroids.

Chiara Zeroli, Armela Gorica, Giulia Monti, Paolo Giocondo Maria Castelnuovo, Maurizio Bignami, Alberto Macchi

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chiara ZeroliENT Clinic ASST Settelaghi, Head and Neck Research Foresic Center, Insubria University, Varese, Italy.
Armela GoricaENT Clinic ASST Settelaghi, Head and Neck Research Foresic Center, Insubria University, Varese, Italy.
Giulia MontiENT Clinic ASST Settelaghi, Head and Neck Research Foresic Center, Insubria University, Varese, Italy.
Paolo Giocondo Maria CastelnuovoENT Clinic ASST Settelaghi, Head and Neck Research Foresic Center, Insubria University, Varese, Italy.
Maurizio BignamiENT Clinic ASST Lariana, University of Insubria, Como, Italy.
Alberto MacchiENT Clinic ASST Settelaghi, Head and Neck Research Foresic Center, Insubria University, Varese, Italy.
University of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Intranasal corticosteroids (INCs) are the first line of therapy for chronic sinonasal conditions such as rhinitis and rhinosinusitis. Among these, one of the most frequently used is beclomethasone dipropionate (BDP). Over the years many studies have evaluated the efficacy of BDP as part of therapy for chronic rhinosinusitis (CRS) and allergic rhinitis (AR) along with nasal washes, which seems to be very well tolerated. Objective: To analyse the data in the literature regarding the various therapeutic regimens of BDP in different sinonasal disease and their efficacy and tolerability. Materials and methods: Using different search engines, the posology, efficacy, and tolerability of BDP were reviewed and a total of 64 full-length articles were examined for eligibility. After applying inclusion and exclusion criteria, 4 articles were reviewed. Results: BDP is among the group of INCs with significant improvement of nasal symptoms and has good efficacy and safety. Conclusions: BDP nasal spray is one of the most frequently prescribed INC for rhinitis and rhinosinusitis. Treatment with BDP resulted in significant and clinically meaningful improvements in nasal symptoms associated with AR and CRS. BDP is well tolerated, and the safety profile is similar to that of placebo in most patients. These results, in conjunction with the significant benefit reported in subjects with CRS and AR, provide convincing evidence of the overall effectiveness of BDP for the treatment of the full spectrum of sinonasal disease.

Indexed as

Administration, IntranasalBeclomethasoneRandomized Controlled Trials as TopicRhinitisSinusitisAdrenal Cortex HormonesChronic DiseaseGlucocorticoidsHumansAdrenal Cortex HormonesBeclomethasoneGlucocorticoidsallergic rhinitisbeclomethasone dipropionatechronic rhinosinusitisrhinitistopical nasal steroids

Identifiers

PMID38651550
PMCPMC11042551
OpenAlexW4395000339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.